AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 404962 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (AMP)
Number of subjects: 86
Study 404962 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin (CB)
Number of subjects: 86
Study 404962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AMP and CB
Number of subjects: 86
Study 30022457 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized AB phase design
Number of subjects: 0
Study 30022457 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization tests
Number of subjects: 0
Study 30022457 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study 27730703 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 7
Study 27730703 — intervention group
Group type: COMPARATOR
Intervention: Stimulation off state
Number of subjects: 7
Study 25470228 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 325
Study 22906113 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal strategies (importance and outcome)
Number of subjects: 126
Study 22906113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 126
Study 22906113 — intervention group
Group type: COMPARATOR
Intervention: No regulation instructions (control group)
Number of subjects: 126
Study 21320227 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency group (employment-based reinforcement)
Number of subjects: 35
Study 21320227 — intervention group
Group type: COMPARATOR
Intervention: Prescription group (standard prescription)
Number of subjects: 35
Study 21320227 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 19961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission blood glucose < 6.1 mmol/L
Number of subjects: 7446
Study 19961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission blood glucose 6.1 to 7.7 mmol/L
Number of subjects: 7446
Study 19961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission blood glucose > 13.0 mmol/L
Number of subjects: 7446
Study 19961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission blood glucose < 6.1 mmol/L in known diabetes
Number of subjects: 7446
Study 19961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission blood glucose 6.1 to 7.7 mmol/L in known diabetes
Number of subjects: 7446
Study 19961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission blood glucose > 13.0 mmol/L in known diabetes
Number of subjects: 7446
Study 17333120 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (magnetic field of 1.5 mT)
Number of subjects: 31
Study 17333120 — intervention group
Group type: COMPARATOR
Intervention: Control group (magnetic field at 0.05 mT)
Number of subjects: 31
Study 15014355 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 500/600 mg/m + folinic acid with or without trimetrexate
Number of subjects: 17
Study 15014355 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study 11123736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent IT morphine (5 microg x kg(‐1) four times a day)
Number of subjects: 12
Study 11123736 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of bupivacaine (40 microg x kg(‐1) x h(‐1)) and morphine (0.6 microg x kg(‐1) x h(‐1))
Number of subjects: 12
Study 9298054 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide hydrochloride
Number of subjects: 109
Study 9298054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular hypertension
Number of subjects: 109
Study 9298054 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 109
Study 8286281 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Follow-Up
Number of subjects: 0
Study 3732501 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational multiple family group
Number of subjects: 40
Study 3732501 — intervention group
Group type: COMPARATOR
Intervention: Traditional multiple family group with a process orientation
Number of subjects: 40
Study 30690571 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile DermatoMyositis Activity Index (JDMAI)
Number of subjects: 627
Study 30328767 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive cueing during a reading task
Number of subjects: 26
Study 30328767 — intervention group
Group type: COMPARATOR
Intervention: Neuropsychological treatment (control condition)
Number of subjects: 26
Study 26703917 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril + Hydrochlorothiazide (Z + H) 30 + 12.5 mg
Number of subjects: 230
Study 26703917 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan + Hydrochlorothiazide (I + H) 150 + 12.5 mg
Number of subjects: 230
Study 26703917 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril + Hydrochlorothiazide (Z + H)
Number of subjects: 230
Study 26703917 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan + Hydrochlorothiazide (I + H)
Number of subjects: 230
Study 24239341 — intervention group
Group type: EXPERIMENTAL
Intervention: ED observation syncope protocol
Number of subjects: 124
Study 23117779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (10 or 5 mg/d)
Number of subjects: 2564
Study 23117779 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 2564
Study 23117779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (5 mg/d for specific populations)
Number of subjects: 2564
Study 23117779 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d for specific populations)
Number of subjects: 2564
Study 23117779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (5 mg/d for older participants)
Number of subjects: 2564
Study 23117779 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d for older participants)
Number of subjects: 2564
Study 23117779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 2564
Study 23117779 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2564
Study 23117779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel and Clopidogrel
Number of subjects: 2564
Study 20122047 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT) for minor depression
Number of subjects: 582
Study 20122047 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 582
Study 16865541 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment anxiety
Number of subjects: 755
Study 16865541 — intervention group
Group type: EXPERIMENTAL
Intervention: Current relationship with the father of the baby
Number of subjects: 755
Study 16224053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg qd for 6 months
Number of subjects: 145
Study 16224053 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg qd for 6 months
Number of subjects: 145
Study 16224053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no statin therapy)
Number of subjects: 145
Study 12589186 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diets (monounsaturated fatty acids)
Number of subjects: 0
Study 12589186 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diets (fruits, vegetables, low-fat dairy)
Number of subjects: 0
Study 12589186 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets high in fiber
Number of subjects: 0
Study 12589186 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous fibers
Number of subjects: 0
Study 12589186 — intervention group
Group type: COMPARATOR
Intervention: Reduction of fat intake
Number of subjects: 0
Study 11018806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (45 mg)
Number of subjects: 10
Study 11018806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8979381 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-triggered facial affect in transference with positively toned significant other descriptors
Number of subjects: 0
Study 8979381 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-triggered facial affect in transference with negatively toned significant other descriptors
Number of subjects: 0
Study 8979381 — intervention group
Group type: COMPARATOR
Intervention: Yoked control participant's descriptors
Number of subjects: 0
Study 8979381 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivations and expectancies in transference
Number of subjects: 0
Study 1330318 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg sumatriptan
Number of subjects: 690
Study 1330318 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg sumatriptan
Number of subjects: 690
Study 1330318 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg sumatriptan
Number of subjects: 690
Study 1330318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study 1330318 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg sumatriptan (open-label for partial or non-responders)
Number of subjects: 690
Study 6322957 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin anticoagulation
Number of subjects: 0
Study 3554658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (250 mg/m2) given twice daily
Number of subjects: 85
Study 3554658 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg)
Number of subjects: 85
Study 3554658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 31587681 — intervention group
Group type: EXPERIMENTAL
Intervention: Contradictory information about carbohydrates and dietary fats
Number of subjects: 901
Study 31587681 — intervention group
Group type: COMPARATOR
Intervention: Established health recommendations
Number of subjects: 901
Study 31587681 — intervention group
Group type: COMPARATOR
Intervention: No information
Number of subjects: 901
Study 29354910 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized scalp acupuncture (ISA)
Number of subjects: 180
Study 29354910 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional scalp acupuncture (CSA)
Number of subjects: 180
Study 29354910 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation group
Number of subjects: 180
Study 26164585 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Number of subjects: 29
Study 26164585 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 100 mg
Number of subjects: 29
Study 26164585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 23553447 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based questionnaire for reporting adverse drug events (ADEs)
Number of subjects: 135
Study 21701406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (10-day regimen: omeprazole with amoxicillin for 5 days, followed by omeprazole, clarithromycin, and metronidazole for 5 days)
Number of subjects: 165
Study 21701406 — intervention group
Group type: COMPARATOR
Intervention: Tailored triple therapy (7-day regimen: omeprazole with amoxicillin and clarithromycin for CLA-susceptible strains or metronidazole for CLA-resistant strains)
Number of subjects: 165
Study 21701406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment in CLA- and MET-susceptible strains
Number of subjects: 165
Study 21701406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment in CLA-resistant strains
Number of subjects: 165
Study 18372036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Awareness Program (CHAP)
Number of subjects: 39
Study 18372036 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 39
Study 16935114 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography
Number of subjects: 106
Study 16935114 — intervention group
Group type: EXPERIMENTAL
Intervention: Transit-time ultrasonic flow measurement
Number of subjects: 106
Study 16935114 — intervention group
Group type: COMPARATOR
Intervention: Comparison of indocyanine green angiography and transit-time flow measurement
Number of subjects: 106
Study 14743545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g orally)
Number of subjects: 19
Study 14743545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11164440 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae IgG antibodies
Number of subjects: 211
Study 11164440 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae IgA antibodies
Number of subjects: 211
Study 11164440 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibody titres
Number of subjects: 211
Study 9206670 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic bone marrow transplantation
Number of subjects: 15
Study 1589246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.2 mg/kg)
Number of subjects: 0
Study 1589246 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (10 mg/kg)
Number of subjects: 0
Study 1589246 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (0.5 mg/kg)
Number of subjects: 0
Study 1589246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3707649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine at increasing doses of 2, 4, and 6 micrograms/kg/min
Number of subjects: 10
Study 3707649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 50 mg
Number of subjects: 10
Study 3707649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg
Number of subjects: 10
Study 3707649 — intervention group
Group type: COMPARATOR
Intervention: Ibopamine 50 mg (on day 1), 100 mg (on day 2), and dopamine (on day 3)
Number of subjects: 10
Study 30081801 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 114
Study 30081801 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 114
Study 25677503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compression bandage
Number of subjects: 52
Study 25677503 — intervention group
Group type: COMPARATOR
Intervention: Cold pack
Number of subjects: 52
Study 24447651 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg sugammadex
Number of subjects: 8
Study 24447651 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/kg sugammadex
Number of subjects: 8
Study 24447651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24447651 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro (200 μg/mL sugammadex)
Number of subjects: 8
Study 22143691 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine hydrochloride with epinephrine 1:100,000
Number of subjects: 96
Study 22143691 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine hydrochloride with epinephrine 1:100,000
Number of subjects: 96
Study 20078487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (450 mg/day)
Number of subjects: 111
Study 20078487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride (800 mg/day)
Number of subjects: 111
Study 20078487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (10 mg/day)
Number of subjects: 111
Study 18393011 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 15767382 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive listening home visits by a support health visitor (SHV)
Number of subjects: 731
Study 15767382 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from community groups providing drop in sessions, home visiting and/or telephone support (CGS)
Number of subjects: 731
Study 15767382 — intervention group
Group type: COMPARATOR
Intervention: Standard health visitor services (Control)
Number of subjects: 731
Study 12813194 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative gated SPECT (QGS)
Number of subjects: 50
Study 12813194 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 50
Study 10613304 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRx (5 Gy equivalent per fraction, 3-5 weekly fractions) with iodinated x-ray contrast media for dose enhancement
Number of subjects: 8
Study 10613304 — intervention group
Group type: COMPARATOR
Intervention: Control tumor (not treated with CTRx)
Number of subjects: 8
Study 7485697 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms of recombinant HB vaccine given at birth, two, and six months of age (group A)
Number of subjects: 590
Study 7485697 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms of recombinant HB vaccine given at two, four, and nine months of age (group B)
Number of subjects: 590
Study 7485697 — intervention group
Group type: COMPARATOR
Intervention: Routine childhood vaccines (BCG, DPT, polio, and measles) given to all groups
Number of subjects: 590
Study 2277251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate prepregnancy maternal alcohol intake
Number of subjects: 2002
Study 2277251 — intervention group
Group type: COMPARATOR
Intervention: Control (no alcohol intake)
Number of subjects: 2002
Study 6997620 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE
Number of subjects: 40
Study 6997620 — intervention group
Group type: COMPARATOR
Intervention: BG
Number of subjects: 40
Study 30602420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Navigable Small World graphs (HNSW)
Number of subjects: 0
Study 30602420 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30995328 — intervention group
Group type: EXPERIMENTAL
Intervention: US (ultrasound)
Number of subjects: 40
Study 30995328 — intervention group
Group type: COMPARATOR
Intervention: USSS (ultrasound with neurostimulation)
Number of subjects: 40
Study 29315462 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of oral aprepitant
Number of subjects: 66
Study 29315462 — intervention group
Group type: COMPARATOR
Intervention: Oral starch (control group)
Number of subjects: 66
Study 26899608 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX administration (uni-DEX and bilateral-DEX groups)
Number of subjects: 45
Study 26899608 — intervention group
Group type: COMPARATOR
Intervention: Saline administration (uni-saline group)
Number of subjects: 45
Study 25214310 — intervention group
Group type: EXPERIMENTAL
Intervention: Amberg‐Schwandorf Algorithm for Primary Triage (ASAV)
Number of subjects: 780
Study 25214310 — intervention group
Group type: COMPARATOR
Intervention: mSTaRT
Number of subjects: 780
Study 23039397 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous (SIM) breast expression
Number of subjects: 31
Study 23039397 — intervention group
Group type: COMPARATOR
Intervention: Sequential (SEQ) breast expression
Number of subjects: 31
Study 21070920 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 332
Study 21070920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 17705848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeck Reaction Perimeter treatment, administered twice weekly for an average of 8.2 months, each session lasting 45 minutes.
Number of subjects: 20
Study 17705848 — intervention group
Group type: COMPARATOR
Intervention: Monocular treatment conditions
Number of subjects: 20
Study 17705848 — intervention group
Group type: COMPARATOR
Intervention: Binocular treatment
Number of subjects: 20
Study 14647884 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subglottic suctioning and semi‐recumbent body position
Number of subjects: 97
Study 14647884 — intervention group
Group type: COMPARATOR
Intervention: Standard care and supine position (Control)
Number of subjects: 97
Study 14647884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 12718823 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological diagnostic tools (sputum culture, throat swab culture, PCR, blood cultures, Legionella urinary antigen, serologic evaluations)
Number of subjects: 318
Study 12718823 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation and treatment for CAP
Number of subjects: 318
Study 12718823 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptoms and radiologic evaluations
Number of subjects: 318
Study 12718823 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiologic survey of CAP
Number of subjects: 318
Study 9581666 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0, 5, and 10 mg)
Number of subjects: 9
Study 9581666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0, 0.5, and 1 g/kg)
Number of subjects: 9
Study 9581666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol-Isradipine combinations
Number of subjects: 9
Study 9581666 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine pretreatment
Number of subjects: 9
Study 7982440 — intervention group
Group type: EXPERIMENTAL
Intervention: Na+/H+ antiport activity in lymphocytes from patients with essential hypertension (Ht)
Number of subjects: 26
Study 7982440 — intervention group
Group type: COMPARATOR
Intervention: NaCl intake of 300 mmol d-1 in normotensive control subjects (Nt)
Number of subjects: 26
Study 7982440 — intervention group
Group type: COMPARATOR
Intervention: NaCl intake of 20, 85, 200, and 300 mmol d-1 for 7 days in normotensive volunteers
Number of subjects: 26
Study 7982440 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl intake of 20 vs. 300 mmol d-1 for 1 week in Ht patients
Number of subjects: 26
Study 7982440 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl intake of 20 vs. 300 mmol d-1 for 1 week in normotensive volunteers
Number of subjects: 26
Study 3059221 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (dosages not specified)
Number of subjects: 0
Study 3059221 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate
Number of subjects: 0
Study 31705332 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of prescription drug co-payments (€0.50 to €2.50) for medical cardholders
Number of subjects: 2
Study 31705332 — intervention group
Group type: EXPERIMENTAL
Intervention: €0.50 co-payment introduction in 2010
Number of subjects: 2
Study 29673337 — intervention group
Group type: EXPERIMENTAL
Intervention: CICA programme (Alcohol Health Champions training)
Number of subjects: 0
Study 27225678 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (precontoured locking plates placed either superiorly or anteriorly)
Number of subjects: 85
Study 27225678 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 85